A certificate of analysis should be evidence, not a sales do...
Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.
Newsletters and Deep Dive digital magazine
Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.
Blackstone Life Sciences will provide up to $1.5bn in funding to Pfizer for the development of its once-monthly GLP-1 agonist berobenatide.
Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.
Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.
New data on Levicept's LEVI-04 in patients with osteoarthritis support its potential to become the first new systemic treatment in over two decades.
Editor's Picks
Newsletters and Deep Dive
digital magazine